Loading…
Stoke Therapeutics, Inc. is projected to rise to $42.26 by 2027, a +29% move from its current price of $32.83. STOK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $32.20 | $32.85 | $33.51 | +0.05% |
| Jul 13 | $31.95 | $32.86 | $33.81 | +0.11% |
| Jul 14 | $31.76 | $32.88 | $34.04 | +0.16% |
| Jul 15 | $31.61 | $32.90 | $34.24 | +0.21% |
| Jul 16 | $31.47 | $32.92 | $34.42 | +0.26% |
| Jul 17 | $31.36 | $32.93 | $34.59 | +0.32% |
| Jul 18 | $31.25 | $32.95 | $34.74 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.25 | $32.95 | $34.74 | +0.37% |
| Week 2 | $30.69 | $33.07 | $35.65 | +0.74% |
| Week 3 | $30.28 | $33.20 | $36.39 | +1.11% |
| Week 4 | $29.97 | $33.32 | $37.04 | +1.49% |
| Week 5 | $29.70 | $33.44 | $37.65 | +1.86% |
| Week 6 | $29.48 | $33.57 | $38.22 | +2.24% |
| Week 7 | $29.28 | $33.69 | $38.76 | +2.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. It uses its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc.
for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc.
in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc. (STOK) operates in the Healthcare sector as a developer of treatments for severe genetic diseases. The stock trades with a current price of $31.00 and a market capitalization of $1.93B, and it is ranked 2055 by market metric.
The forecasted price trajectory shows upside across multiple years, with an expected rise in average price from 2026 through 2050 and substantial ROIs in later years.
A major floor 19.5% below — a decisive break under it would weaken the trend.
The nearest floor, 13.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.6% away) — a breakout level to watch.
A major ceiling 16.8% above — clearing it would confirm fresh momentum.
Key STOK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STOK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $32.46 | Buy | $32.25 | Buy |
| MA 10 | $32.48 | Buy | $32.13 | Buy |
| MA 20 | $31.36 | Buy | $31.68 | Buy |
| MA 50 | $31.18 | Buy | $31.62 | Buy |
| MA 100 | $32.81 | Buy | $31.59 | Buy |
| MA 200 | $31.41 | Buy | $29.36 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.85 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 0.92 | Neutral |
| Williams %R (14) | -62.36 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | 0.87 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 37.64 | Neutral |
| TRIX (15) | 0.17 | Buy |
| Awesome (5,34) | 1.67 | Buy |
| Ultimate (7,14,28) | 37.80 | Neutral |
| Momentum (10) | 0.98 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 32.42 | Buy |
| ADX (14) | 15.05 | Neutral |
| ATR (14) | 0.55 | Info |
The near-term technical picture reflects a bullish tone, with sentiment labeled BULLISH and RSI(14) at 50. The 50-day simple moving average sits at $32.07 and the 200-day simple moving average at $30.74, indicating near-term resistance around the mid-$30s and support near the high $20s. The 30-day range spans from $26.72 to $35.97, with a near-term support at $28.48 and a resistance at $32.89.
Annualized volatility stands at 40%, underscoring elevated price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.48 | $32.83 | $45.30 | 0% | Neutral | |
| $34.48 | $42.26 | $54.26 | +29% | Bullish | |
| $41.82 | $52.30 | $69.07 | +59% | Bullish | |
| $46.37 | $58.94 | $79.59 | +80% | Bullish | |
| $50.02 | $64.51 | $88.76 | +96% | Bullish | |
| $51.96 | $67.87 | $94.95 | +107% | Bullish | |
| $53.87 | $71.23 | $101.13 | +117% | Bullish | |
| $63.68 | $85.14 | $122.53 | +159% | Bullish | |
| $73.85 | $99.81 | $145.44 | +204% | Bullish | |
| $79.44 | $108.45 | $159.88 | +230% | Bullish | |
| $110.71 | $158.14 | $244.87 | +382% | Bullish | |
| $193.62 | $298.32 | $496.72 | +809% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.48 | $32.83 | $38.58 | +0.00% |
| August 2026 | $28.60 | $33.52 | $40.18 | +2.12% |
| September 2026 | $29.24 | $34.45 | $41.62 | +2.75% |
| October 2026 | $29.12 | $34.45 | $41.92 | +0.02% |
| November 2026 | $29.64 | $35.20 | $43.08 | +2.16% |
| December 2026 | $30.89 | $36.81 | $45.30 | +4.59% |
Click any year to see its month-by-month STOK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Stoke Therapeutics, Inc.'s 2026 outlook centres on $32.83, within a $28.48 to $45.30 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, STOK could reach as high as $54.26, with a base case around $42.26 and support toward $34.48 — roughly +29% from $32.83. Buyers look set to stay in control over this stretch.
Expect STOK to range from $41.82 to $69.07 through 2028. The $52.30 average target implies a +59% move from current prices. That is up +24% on the projected 2027 average. Momentum favours further upside here.
The STOK price prediction for 2029 points to an average of $58.94 (low $46.37, high $79.59) — a potential gain of +80% on today's $32.83. Buyers look set to stay in control over this stretch.
In 2030, STOK is projected to trade between $50.02 and $88.76, averaging $64.51 — a potential gain of +96% from today's $32.83. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Stoke Therapeutics, Inc.'s 2031 outlook centres on $67.87, within a $51.96 to $94.95 range. That is up +5% on the projected 2030 average. That marks a +107% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, STOK could reach as high as $101.13, with a base case around $71.23 and support toward $53.87 — roughly +117% from $32.83. Momentum favours further upside here.
Expect STOK to range from $63.68 to $122.53 through 2033. The $85.14 average target implies a +159% move from current prices. That is up +20% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The STOK price prediction for 2034 points to an average of $99.81 (low $73.85, high $145.44) — a potential gain of +204% on today's $32.83. Momentum favours further upside here.
In 2035, STOK is projected to trade between $79.44 and $159.88, averaging $108.45 — a potential gain of +230% from today's $32.83. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Stoke Therapeutics, Inc.'s 2040 outlook centres on $158.14, within a $110.71 to $244.87 range. That is up +46% on the projected 2035 average. That marks a +382% change versus current levels. Momentum favours further upside here.
By 2050, STOK could reach as high as $496.72, with a base case around $298.32 and support toward $193.62 — roughly +809% from $32.83. Buyers look set to stay in control over this stretch.
Investing $1,000 in STOK today (≈ 30.459945 STOK) could be worth
$9,086.75
+$8,086.75 (+809%) by 2050 · US Dollar
Based on the average projected STOK price of $298.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STOKwould be worth at today's price.
$1,000 invested in STOK on Jul 10, 2025 (≈ 83.056479 STOK) would be worth
$2,726.74
+$1,726.74 (+172.7%) today · 2.73× · US Dollar
Based on a STOK entry price of $12.04 vs. today's $32.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $32.7 | $1,003.98 | +0.4% |
| 1 month ago | $28.48 | $1,152.74 | +15.3% |
| 3 months ago | $34.33 | $956.31 | -4.4% |
| 6 months ago | $29.42 | $1,115.91 | +11.6% |
| 1 year ago | $12.04 | $2,726.74 | +172.7% |
| All time (5.0y) ago | $34.44 | $953.25 | -4.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STOK forecast.
Our base-case forecast reaches $66.00 around 2031.
Implied market cap at $66.00: $4.11B
The multi-year forecast paints a bullish path for Stoke Therapeutics, with the average price rising from $31.00 in 2026 to higher levels in subsequent years. Notable year-by-year milestones include a 2027 average of $40.34 (ROI 30.1%), 2028 average $52.18 (ROI 68.3%), 2029 average $58.46 (ROI 88.6%), and 2030 average $62.60 (ROI 101.9%). The forecast continues to show strong momentum, with 2031 $68.31 (120.3%), 2032 $71.26 (129.9%), and 2033 $85.83 (176.9%), 2034 $103.56 (234.1%), 2035 $108.99 (251.6%).
By 2040, the average price is $166.66 (ROI 437.6%), and by 2050 it is $312.48 (ROI 908%). The bullish outlook comes with inherent uncertainty and the numbers are estimates, not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $47.76, avg $62.60, max $87.95; ROI 101.9; sentiment BULLISH.
The forecast shows bullish sentiment across multiple years, with higher averages and ROIs: 2027 avg $40.34, 2030 avg $62.60 (ROI 101.9), 2040 avg $166.66 (ROI 437.6), and 2050 avg $312.48 (ROI 908). These are estimates, not guarantees.
Yes. 2033 max is $126.66; 2033 avg $85.83; min $62.82.
Current price is $31.00 and market cap is $1.93B.
Sentiment BULLISH; RSI(14) 50; SMA50 $32.07; SMA200 $30.74; 30-day range $26.72-$35.97; support $28.48; resistance $32.89; annualized volatility 40%.
Stoke Therapeutics, Inc. Community Discussion
0Share your Stoke Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.